General Information of the Protein
Protein ID
PT01151
Protein Name
Amyloid-beta precursor protein
Secondarily
Protein Name
ABPP
APPI
Alzheimer disease amyloid A4 protein homolog
Alzheimer disease amyloid protein
Amyloid precursor protein
Amyloid-beta (A4) precursor protein
Amyloid-beta A4 protein
Cerebral vascular amyloid peptide
PreA4
Protease nexin-II
Beta-secretase C-terminal fragment
Beta-APP42
Beta-APP40
Alpha-secretase C-terminal fragment
Amyloid intracellular domain 59
Gamma-CTF(59)
Amyloid intracellular domain 57
Gamma-CTF(57)
Amyloid intracellular domain 50
Gamma-CTF(50)
Gene Name
APP
Secondarily
Gene Name
A4
AD1
Sequence
MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEEEADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
    Show/Hide
Organism
Homo sapiens, Human
Protein Classification
Membrane receptor
Function
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed:25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed:17062754, PubMed:23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.
    Show/Hide
Uniprot ID
Primary ID:
P05067

Secondarily ID:
B2R5V1
B4DII8
D3DSD1
D3DSD2
D3DSD3
P09000
P78438
Q13764
Q13778
Q13793
Q16011
Q16014
Q16019
Q16020
Q6GSC0
Q8WZ99
Q9BT38
Q9UC33
Q9UCA9
Q9UCB6
Q9UCC8
Q9UCD1
Q9UQ58
    Show/Hide
Ensembl ID
ENSG00000142192
HGNC ID
HGNC:620
Subcellular Location
Cell membrane
Membrane
Perikaryon
Cell projection
Growth cone
Membrane
Clathrin-coated pit
Early endosome
Cytoplasmic vesicle
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein

Protein
Cell Line
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000758 , CHO-N9
Compound ID Compound Name Compound Formula
CP0500590
(2R,3S)-N1-((S)-1-(3-(phenylamino)benzyl)-2-oxoazepan-3-yl)-2-isobutyl-3-propylsuccinamide
   Show/Hide
C30H42N4O3
 1
1
IC50 = 15 nM
   TI
   LI
   LO
   TS
CP0516391
(2S,3R)-N'-[(3S)-1-[[3-(3-methylanilino)phenyl]methyl]-2-oxoazepan-3-yl]-3-(2-methylpropyl)-2-propylbutanediamide
   Show/Hide
C31H44N4O3
 1
1
IC50 = 17 nM
   TI
   LI
   LO
   TS
CP0559374
(2S,3R)-N'-[(3S)-1-[[3-(3-chloro-4-fluoroanilino)phenyl]methyl]-2-oxoazepan-3-yl]-3-(2-methylpropyl)-2-propylbutanediamide
   Show/Hide
C30H40ClFN4O3
 1
1
IC50 = 17 nM
   TI
   LI
   LO
   TS
CP0407919
(2S,3R)-N'-[(3S)-1-[[3-(2-chloroanilino)phenyl]methyl]-2-oxoazepan-3-yl]-3-(2-methylpropyl)-2-propylbutanediamide
   Show/Hide
C30H41ClN4O3
 1
1
IC50 = 29 nM
   TI
   LI
   LO
   TS
CP0394247
(2S,3R)-3-(2-methylpropyl)-N'-[(3S)-2-oxo-1-[[3-[4-(trifluoromethyl)anilino]phenyl]methyl]azepan-3-yl]-2-propylbutanediamide
   Show/Hide
C31H41F3N4O3
 1
1
IC50 = 30 nM
   TI
   LI
   LO
   TS
CP0442161
(2S,3R)-N'-[(3S)-1-[[3-(3-methoxyanilino)phenyl]methyl]-2-oxoazepan-3-yl]-3-(2-methylpropyl)-2-propylbutanediamide
   Show/Hide
C31H44N4O4
 1
1
IC50 = 54 nM
   TI
   LI
   LO
   TS
CP0442160
(2S,3R)-3-(2-methylpropyl)-N'-[(3S)-2-oxo-1-[[3-(piperidin-1-ylamino)phenyl]methyl]azepan-3-yl]-2-propylbutanediamide
   Show/Hide
C29H47N5O3
 1
1
IC50 = 74 nM
   TI
   LI
   LO
   TS
CP0485594
(2S,3R)-N'-[(3S)-1-[[3-(1,3-benzodioxol-5-ylamino)phenyl]methyl]-2-oxoazepan-3-yl]-3-(2-methylpropyl)-2-propylbutanediamide
   Show/Hide
C31H42N4O5
 1
1
IC50 = 152 nM
   TI
   LI
   LO
   TS
CP0393507
(2S,3R)-N'-[(3S)-1-[[3-(4-methoxyanilino)phenyl]methyl]-2-oxoazepan-3-yl]-3-(2-methylpropyl)-2-propylbutanediamide
   Show/Hide
C31H44N4O4
 1
1
IC50 = 160 nM
   TI
   LI
   LO
   TS
CP0000226
(2R,3S)-N1-((S)-1-(3-phenoxybenzyl)-2-oxoazepan-3-yl)-N4-hydroxy-2-isobutyl-3-propylsuccinamide
   Show/Hide
C30H41N3O5
 1
1
IC50 = 200 nM
   TI
   LI
   LO
   TS
CP0407918
(2R,3S)-2-(2-methylpropyl)-N-[(3S)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]-N'-[(E)-4-phenylbut-2-enyl]-3-propylbutanediamide
   Show/Hide
C40H51N3O4
 1
1
IC50 = 3000 nM
   TI
   LI
   LO
   TS
CP0453285
(2S,3R)-N-(furan-2-ylmethyl)-3-(2-methylpropyl)-N'-[(3S)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]-2-propylbutanediamide
   Show/Hide
C35H45N3O5
 1
1
IC50 = 3000 nM
   TI
   LI
   LO
   TS
CP0442159
(2S,3R)-N-butyl-3-(2-methylpropyl)-N'-[(3S)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]-2-propylbutanediamide
   Show/Hide
C34H49N3O4
 1
1
IC50 = 5000 nM
   TI
   LI
   LO
   TS
CP0394246
(2S,3R)-N-cyclopentyl-3-(2-methylpropyl)-N'-[(3S)-2-oxo-1-[(3-phenoxyphenyl)methyl]azepan-3-yl]-2-propylbutanediamide
   Show/Hide
C35H49N3O4
 1
1
IC50 = 6000 nM
   TI
   LI
   LO
   TS
CP0442158
(2R,3S)-N-[(3S)-1-benzyl-2-oxoazepan-3-yl]-N'-hydroxy-2-(2-methylpropyl)-3-propylbutanediamide
   Show/Hide
C24H37N3O4
 1
1
IC50 = 6800 nM
   TI
   LI
   LO
   TS
Biochemical Assays
Compound ID Compound Name Compound Formula
CP0012593
4-(4-Chloro-benzenesulfonyl)-4-(2-methoxy-phenyl)-piperidine-1-carboxylic acid ethyl ester
   Show/Hide
C21H24ClNO5S
 2
1 EC50 = 3500 nM
2 EC50 = 5000 nM
CP0067359
(2R)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid
   Show/Hide
C18H16O8
 2
1 EC50 = 20300 nM
2 IC50 = 71900 nM
CP0006184
6,7,13,14-tetrahydroxy-2,9-dioxatetracyclo[6.6.2.0^{4,16}.0^{11,15}]hexadeca-1(14),4(16),5,7,11(15),12-hexaene-3,10-dione
   Show/Hide
C14H6O8
 3
1 EC50 = 562559.9788 nM
2 EC50 = 6000000000 nM
3 IC50 = 100000 nM
CP0080580
4,40-(1E,10E)-2,20-(Isoxazole-3,5-diyl)bis(ethene-2,1-diyl)bis(2-methoxyphenol)
   Show/Hide
C21H19NO5
 1
1 IC50 = 138 nM
CP0062008
CHEBI:3962
   Show/Hide
C21H20O6
 15
1 IC50 = 900 nM
2 IC50 = 1000 nM
3 IC50 = 1500 nM
4 IC50 = 3100 nM
5 IC50 = 3400 nM
6 IC50 = 3850 nM
7 IC50 = 6385 nM
8 IC50 = 8270 nM
9 IC50 = 11300 nM
10 IC50 = 13700 nM
11 IC50 = 14990 nM
12 IC50 = 16250 nM
13 IC50 = 18730 nM
14 IC50 = 21810 nM
15 IC50 = 22510 nM
CP0165238
(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 2-[(5E)-5-[(10-methylphenothiazin-3-yl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetate
   Show/Hide
C25H24N2O5S3
 1
1 Kd = 24.5 nM
Clinical Information about the Protein
Target 1 ( Amyloid beta A4 protein (APP) )
Target Type Successful Target
Disease 2 Target-related Diseases  2
1 Solid tumour/cancer [ICD-11: 2A00-2F9Z]
2 Alzheimer disease [ICD-11: 8A20]
Clinical Trial Drug(s) 4 Clinical Trial Drugs  4
1 Curcumin Phase 3
Solid tumour/cancer
2 Tramiprosate Phase 3
Alzheimer disease
3 AD-35 Phase 2
Alzheimer disease
4 T-817MA Phase 2
Alzheimer disease
Investigative Drug(s) 1 Investigative Drug  1
1 ELND-007 Investigative
Alzheimer disease
Target 2 ( APP messenger RNA (APP mRNA) )
Target Type Clinical trial Target